Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17707215 | MEDIUM FOR CULTURING HEPATOCYTE, METHOD OF PRODUCING HEPATOCYTE, AND HEPATOCYTE | Final Rejection | FUJIFILM Corporation |
| 18774971 | METHODS OF PRODUCING THREE-DIMENSIONAL CELLULAR TISSUES | Non-Final OA | TOPPAN HOLDINGS INC. |
| 17984720 | METHODS, COMPOSITIONS, AND KITS FOR EXPANDING NATURAL KILLER CELLS | Non-Final OA | Regents of the University of Minnesota |
| 18580093 | AUF1 COMBINATION THERAPIES FOR TREATMENT OF MUSCLE DEGENERATIVE DISEASE | Non-Final OA | NEW YORK UNIVERSITY |
| 18683101 | SLC13A5 GENE THERAPY VECTORS AND USES THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18703908 | DEDIFFERENTIATED PLANT CELLS OF THE GENUS PAEONIA, EXTRACTS THEREOF AND COSMETIC USES THEREOF | Non-Final OA | L'OREAL |
| 18379740 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | Non-Final OA | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY |
| 18265544 | COMPOUNDS AND METHODS TO TREAT CYSTIC FIBROSIS | Non-Final OA | City of Hope |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy